Vol. 02 Issue 07   Friday  June 27, 2008
                         APIs

  
  Commercial
Scale

  Antitubercular
  Pyrazinamide
  Isoniazid
  Rifampicin
  Antimalarial
  Artesunate
  Arteether
  Artemether
  Dihydroartemisinin
  Lumefantrine

  Macrolides
  Azithromycin
  Erythromycin base
  Erythromycin estolate
  Erythromycin ethylsuccinate
  Erythromycin oxime  (intermediate)
  Erythromycin phosphate
  Erythromycin propionate
  Erythromycin stearate
  Antihypertensive
  Lisinopril dihydrate
  Losartan potassium
  Irbesartan
  Valsartan
  Antiepileptic
  Sodium valproate
  Valproic acid
  Divalproex sodium
  Antiosteoporotic
  Alendronate sodium
  Sedative, Hypnotic
  Zopiclone
  Antidepressant
  Venlafaxine hydrochloride
  Antihistaminic   
  Cetirizine dihydrochloride
  Antithrombotic
  Clopidogrel bisulphate
 

  Pilot Plant Scale
  Carvedilol
  Clarithromycin
  Pioglitazone hydrochloride
  Rosiglitazone maleate
  
  R & D Scale

  Eszopiclone

  Development
  Benazepril hydrochloride
  Candesartan
  Desvenlafaxine
  Eprosartan
  Levocetirizine
  Olmesartan
  Ramipril
  Rifabutin
  Rifapentine
  Risedronic acid
  Telmisartan

      Product under patent  offered  only
      for exempted research, clinical and
      development  purposes. Only  non-
      infringing   products   and  processes
      are offered, subject to patent status
      verification by client.
Calyx at Chemspec Europe 2008

Calyx received good response during the recent ‘Chemspec Europe 2008’ event held in Munich, Germany from June 18 – 19, 2008. There were potential business meetings with our customers and this event provided us an additional platform for showcasing our custom manufacturing and custom synthesis capabilities. We take this opportunity to thank each and every visitor to the Calyx Stand at Chemspec Europe 2008, for their valuable time and attention.



Calyx at CPhI China 2008
The ‘CPhI China 2008’ at Shanghai was held during 24 - 26 June 2008. It was the biggest annual networking and business opportunity for Asia's pharmaceutical ingredients and services community. There were nearly 1600 exhibitors from 20 countries and almost 20000 attendees.

Calyx participated in the event with a booth in Hall 1 for international exhibitors. There was a tremendous response both by way of scheduled meetings, walk-in visitors and also during visits to booths of other exhibitors. Calyx sources many materials from China for its established APIs and also for new development projects. The event resulted in consolidation of Calyx presence in China, with better relationships for continuous supply of the raw materials.

GC Lab at Calyx R&D commissioned

Recently we have commissioned an additional GC Lab at our new R & D facility. This Lab houses 8 GCs, 1 GC-MS and GC with headspace. The GC Lab will cater to in – house as well as external customers for identifying and analyzing samples having vapour pressure. Residual solvents with dilution limits as low as 0.2 ppm can be analysed by Headspace GC.

Services
             
             Custom Synthesis                                        FTE and FFS                                     Building Blocks

             Contract Research                                      APIs and Intermediates                     Analytical Services

             Contract Manufacturing
  Disclaimer:
 "The information in this e-mail and any attachments is confidential and may be legally privileged. It is intended solely for the addressee or addressees. If you are not an intended recipient, please delete the  message and any   attachments and notify the sender of  misdelivery. Any use or disclosure of  the  contents of either is unauthorized  and  may   be unlawful. All  liability  for viruses is excluded to the fullest   extent permitted by law. Any views   expressed in this message  are those of the individual sender, except where the sender   states them, with requisite authority, to be those of the specific Calyx company."
To unsubscribe from this Newsletter send blank email to pharmanews@calyxindia.com
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------